Inhaled 'Smart' particles aim to halt lung scarring

NCT ID NCT07571291

Ongoing Disease control Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is developing a new way to treat pulmonary fibrosis, a condition where the lungs become scarred and stiff. The approach uses tiny particles called liposomes, coated with hyaluronic acid, to deliver drugs directly to the cells that cause scarring. The research is being done in the lab and in mice, using cells and tissues from 30 patients, to see if the particles are safe and can target the right cells.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: liposomes coated with hyaluronic acid (XHALIP)
What this could lead to: If successful, this could lead to a more targeted, inhaled treatment for pulmonary fibrosis with fewer side effects.
What could go wrong: This is a very early, small lab and animal study. It may not translate to humans, and the liposome technology is still experimental.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic pulmonary fibrosis pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PULMONARY FIBROSIS

Contacts and locations

Locations

Rheumatology unit IRCCS Policlinico San Matteo Pavia

Pavia, 27100, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.